NCT01503515 is a Phase 3 clinical trial of Caspofungin Acetate in Fungal Infection, sponsored by Children's Oncology Group.

Who is sponsoring NCT01503515?

NCT01503515 is sponsored by Children's Oncology Group.

What drugs are being tested in NCT01503515?

Interventions in NCT01503515: Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis, Voriconazole.

What condition does NCT01503515 study?

NCT01503515 studies Fungal Infection, Hematopoietic and Lymphoid Cell Neoplasm.

Is NCT01503515 still recruiting?

NCT01503515 is currently completed. Last updated 16 October 2024.

Are results published for NCT01503515?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-10-16 · How we verify

NCT01503515

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

Completed Phase 3 Results posted Last updated 16 October 2024

What this trial tests

Phase 3 trial testing Caspofungin Acetate in Fungal Infection in 292 participants. Completed in 30 September 2021.

Timeline

21 March 2013

Primary endpoint
31 December 2019

30 September 2021

Quick facts

Lead sponsor	Children's Oncology Group
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	292
Start date	21 March 2013
Primary completion	31 December 2019
Estimated completion	30 September 2021
Sites	49 locations across United States, Canada

Drugs / interventions tested

Caspofungin Acetate — full drug profile →
Fluconazole (fluconazole) — full drug profile →
Laboratory Biomarker Analysis — full drug profile →
Voriconazole — full drug profile →

Conditions studied

Fungal Infection — all drugs for Fungal Infection →
Hematopoietic and Lymphoid Cell Neoplasm — all drugs for Hematopoietic and Lymphoid Cell Neoplasm →

Sponsor

Children's Oncology Group — full company profile →

Who can join

Adults 3 Months to 20, any sex, with Fungal Infection or Hematopoietic and Lymphoid Cell Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized phase III trial studies how well caspofungin acetate works compared to fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant. Caspofungin acetate, fluconazole, and voriconazole may be effective in preventing fungal infections in patients following donor stem cell transplant. It is not yet known whether caspofungin acetate is more effective than fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplant.
Dvorak CC, Fisher BT, Esbenshade AJ, Nieder ML, et al · · 2021 · cited 18× · PMID 33136159 · DOI 10.1093/jpids/piaa119

Verify or expand the search:

Other trials of Caspofungin Acetate

Trials testing the same drug.

NCT04728971 — To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation · Phase 4 · unknown
NCT01307579 — Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Ac · Phase 3 · completed

Other recruiting trials for Fungal Infection

Currently open trials in the same condition.

NCT07238114 — Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors · active not recruiting
NCT06510699 — Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial · Phase 2 · recruiting
NCT05814432 — Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS · Phase 3 · recruiting
NCT03717623 — Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants · Phase 4 · recruiting
NCT03828773 — PTX3-targeted Antifungal Prophylaxis · NA · recruiting

Other Children's Oncology Group trials

Trials by the same sponsor.

NCT07412002 — Quality of End-of-Life Care for Children With Cancer · not yet recruiting
NCT07498465 — A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant · Phase 1 · withdrawn
NCT07022678 — Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia · Phase 3 · not yet recruiting
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT06858501 — Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01503515 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Children's Oncology Group
Last refreshed: 16 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01503515.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing